Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas

10 Jul 2023

Abstract excerpt

Defining reliable surrogate markers and overcoming drug resistance are the most challenging issues for improving therapeutic outcomes of antiangiogenic drugs (AADs) in cancer patients. At the time of this writing, no biomarkers are clinically available to predict AAD therapeutic benefits and drug resistance. Here, we uncovered a unique mechanism of AAD resistance in epithelial carcinomas with KRAS mutations that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Galectins and Cancer Biology
Share to Lipid metabolism and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37428914
DOI: 10.1073/pnas.2303740120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomasPMID 37428914Read ↗

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Semantic proximity Read ↗

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity Read ↗

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Semantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read ↗

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapySemantic proximity Read ↗

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.Semantic proximity Read ↗

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.